Search

Search Constraints

You searched for: Author/Creator Shimada, Noritomo

Search Results

1. A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Issue 14 (15th April 2014)

2. A genome‐wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. (8th August 2021)

3. A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony‐stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. Issue 6 (20th October 2015)

4. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. (22nd July 2021)

5. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

6. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. Issue 6 (19th February 2018)

7. Association between vitamin D deficiency and pre‐existing resistance‐associated hepatitis C virus NS5A variants. Issue 7 (26th August 2016)

8. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Issue 5 (9th February 2022)

9. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Issue 7 (July 2019)

10. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)